- Candel Therapeutics (CADL) – SELL
Lock in a +33% profit. The stock has appreciated on favorable news now priced in. With no significant catalysts expected until 2026, we will sell all 5 shares at ~$6.74 each (≈$33.70 total proceeds).
- Actuate Therapeutics (ACTU) – NEW BUY
Use CADL proceeds and available cash (~$2.32) to purchase approximately 6 shares of ACTU around $6.00 each. ACTU shows promise with positive Phase 2 cancer trial results and upcoming potential upside.
-
Abeona Therapeutics (ABEO) – HOLD
Maintain our 6 shares. Strong cash reserves and the launch of ZEVASKYN position the stock for continued value realization as sales begin to ramp. -
Azitra (AZTR) – HOLD (Speculative)
Retain 55 shares. Despite a slight unrealized loss, we believe the upcoming Phase 1b data for Netherton syndrome (due Q4 2025) is a high-impact binary catalyst. No further buying due to elevated risk. -
Inspira Technologies (IINN) – HOLD/Accumulating
Continue holding 20 shares. The $22.5M order and regained Nasdaq compliance represent key turning points. We will consider adding more shares on pullbacks.
Post-Reallocation Portfolio:
- ABEO
- AZTR
- IINN
- ACTU
- (Small remaining cash reserve)
This strategy secures gains from CADL and reallocates capital toward higher-conviction opportunities. The portfolio remains diversified across both commercial-stage stories (ABEO, IINN) and clinical catalyst plays (ACTU, AZTR). We will continue to monitor news and price action, and remain flexible with risk controls.